When was Receptor Biologix founded?
Receptor Biologix was founded in 2003.
Where is Receptor Biologix's headquarters?
Receptor Biologix's headquarters is located at 3350 West Bayshore Road, Palo Alto.
What is Receptor Biologix's latest funding round?
Receptor Biologix's latest funding round is Acquired.
How much did Receptor Biologix raise?
Receptor Biologix raised a total of $39.6M.
Who are the investors of Receptor Biologix?
Investors of Receptor Biologix include Symphogen, EW Healthcare Partners, New Science Ventures, Takeda Ventures, Domain Associates and 5 more.
Who are Receptor Biologix's competitors?
Competitors of Receptor Biologix include Acceleron Pharma, Dare Bioscience, Bird Rock Bio, AM-Pharma, Array Biopharma and 13 more.
You May Also Like
AM-Pharma is a biopharmaceutical company that focuses on the development of recombinant Alkaline Phosphatase for clinical use.
Iconic Therapeutics is a clinical-stage biopharmaceutical company dedicated to translating scientific knowledge into new medicines. The company's understanding of the role of the tissue factor in angiogenesis, inflammation, and malignancies has led it to a new approach to developing therapies for devastating diseases such as macular degeneration and cancer.
Biopharmaceutical company developing enabling technology platforms and enhanced natural therapeutics for certain infectious diseases, cancers and CNS disorders. Ehanced therapeutics include small molecules from medicinal plants and marine organisms, and improved drug delivery formulations of protein macromolecules and hydrophobic anticancer drugs.
Oxurion is a biopharmaceutical company focused on the development of therapeutics for conditions related to the vascular system. The Company has used its in-house expertise and collaborations with academic institutions to build a strong pipeline of promising drug candidates in cardiovascular diseases, visual disorders, and cancer.
Oligomerix is a biopharmaceutical company focused on development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers and their newly discovered proteolytic enzymatic activity. The Company was founded in 2006 and is located within the Audubon Biomedical Science and Technology Park at Columbia University Medical Center.
Limerick BioPharma is developing compounds that per the company when used adjunctively with both marketed and investigational drugs improve drug side effect profiles and clinical outcomes. By activating cellular transport pumps to redistribute drugs away from organs and tissues where they have adverse effects, the company's compounds aim to minimize toxic side effects at non-targeted vulnerable organs and tissues while maintaining or enhancing a drug's desired effects. Per the company, Limerick's pipeline molecules are applicable to a broad range of therapeutic drug classes including immunosuppressants, opioids, immunomodulators, selective estrogens receptor modulators, and psychotropics. In the monotherapy setting, Limerick is developing novel compounds that target the treatment of metabolic diseases such as hypercholesteremia and hyperglycemia via a mechanism related to reverse cholesterol transport.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.